{"id":53974,"date":"2023-02-15T23:05:26","date_gmt":"2023-02-15T22:05:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/"},"modified":"2023-02-15T23:05:26","modified_gmt":"2023-02-15T22:05:26","slug":"sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/","title":{"rendered":"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So"},"content":{"rendered":"
\n

\nSarissa Assumes That Amarin Knew This Conduct Was Going On and Did Nothing To Stop It<\/b>\n<\/p>\n

\nSarissa Acted to Correct the Issue, Ensuring That All Votes Submitted On The Blue Proxy Card Will Be Counted at the Amarin General Meeting<\/b>\n<\/p>\n

\nAmarin Shareholders That Already Voted on the Blue Proxy Card Do NOT Need to Take Any Action; Your Vote Will be Counted<\/b>\n<\/p>\n

GREENWICH, Conn.–(BUSINESS WIRE)–Sarissa Capital Management LP (\u201cSarissa\u201d) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):\n<\/p>\n

\nSarissa Capital, in voting its shares, uncovered that Amarin\u2019s registrar, the firm retained by Amarin to receive and process proxy cards, had not been instructed to accept blue proxy cards even though legally required to do so. Amarin\u2019s registrar believed it was only authorized to accept and process the white proxy cards. Sarissa assumes this conduct was condoned by, or worse, coordinated with Amarin. We believe this is another attempt by Amarin to entrench themselves and disenfranchise shareholders. Fortunately for shareholders, Sarissa acted to correct this problem and all votes that have been or will be submitted on the blue proxy card will be accepted.\n<\/p>\n

\nIF YOU ALREADY VOTED \u201cFOR\u201d ALL PROPOSALS AND SUBMITTED YOUR BLUE PROXY CARD, THERE IS NOTHING ELSE YOU NEED TO DO TO SUPPORT SARISSA\u2019S NOMINEES. YOU DO NOT NEED TO VOTE AGAIN.<\/b>\n<\/p>\n

\nAmarin is in dire need of change. Sarissa is Amarin\u2019s largest shareholder, owning more than 25 million shares. We are long term shareholders and have not sold any shares since acquiring our position. We have a stellar track record of success, including in the cardiovascular space, and we believe our nominees have the experience and qualifications to help unlock Amarin\u2019s true potential.\n<\/p>\n

\nYou can vote on the blue proxy card or the white proxy card, but if you want to fully support Sarissa, you must make sure that all \u201cFOR<\/b>\u201d boxes are marked on your proxy card (blue or white) before you submit it.\n<\/p>\n

\nIf you have any questions on how to vote, we recommend that you contact Sarissa\u2019s proxy solicitor, D.F. King, by calling (800) 331-7024 or emailing AMRN@dfking.com<\/a>.\n<\/p>\n

\nWe urge all shareholders to vote \u201cFOR<\/b>\u201d the Sarissa Nominees and \u201cFOR<\/b>\u201d the removal of Chairman Per Wold-Olsen on or prior to the deadline on Tuesday, February 21, 2023.\n<\/p>\n

\n#FreeAmarin\n<\/p>\n

\nVisit our website at www.freeamarin.com<\/a> for helpful information about Sarissa and the need for change at Amarin.\n<\/p>\n

\nThe General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023<\/span><\/b>.\n<\/p>\n

\nAdditional Information<\/b>\n<\/p>\n

\nSarissa Capital Management LP (\u201cSarissa Capital\u201d), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the \u201cCompany\u201d) at the general meeting of the Company for the election of Sarissa Capital\u2019s slate of highly-qualified nominees (the \u201cGeneral Meeting\u201d). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.\n<\/p>\n

\nThe definitive proxy statement and other relevant documents are available at no charge on the SEC\u2019s website at www.sec.gov<\/a> and at www.freeamarin.com<\/a>. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital\u2019s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJean Puong
\n
Sarissa Capital Management LP
\n
info@sarissacap.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Sarissa Assumes That Amarin Knew This Conduct Was Going On and Did Nothing To Stop It Sarissa Acted to Correct the Issue, Ensuring That All Votes Submitted On The Blue Proxy Card Will Be Counted at the Amarin General Meeting Amarin Shareholders That Already Voted on the Blue Proxy Card Do NOT Need to Take … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53974","6":"format-standard","7":"category-industry"},"yoast_head":"\nSarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Sarissa Assumes That Amarin Knew This Conduct Was Going On and Did Nothing To Stop It Sarissa Acted to Correct the Issue, Ensuring That All Votes Submitted On The Blue Proxy Card Will Be Counted at the Amarin General Meeting Amarin Shareholders That Already Voted on the Blue Proxy Card Do NOT Need to Take ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-15T22:05:26+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So\",\"datePublished\":\"2023-02-15T22:05:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\\\/\"},\"wordCount\":615,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\\\/\",\"name\":\"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-02-15T22:05:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/","og_locale":"en_US","og_type":"article","og_title":"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So - Pharma Trend","og_description":"Sarissa Assumes That Amarin Knew This Conduct Was Going On and Did Nothing To Stop It Sarissa Acted to Correct the Issue, Ensuring That All Votes Submitted On The Blue Proxy Card Will Be Counted at the Amarin General Meeting Amarin Shareholders That Already Voted on the Blue Proxy Card Do NOT Need to Take ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-15T22:05:26+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So","datePublished":"2023-02-15T22:05:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/"},"wordCount":615,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/","url":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/","name":"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-02-15T22:05:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sarissa-capital-uncovers-that-amarins-registrar-had-not-been-instructed-to-accept-blue-proxy-cards-even-though-legally-required-to-do-so\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sarissa Capital Uncovers That Amarin\u2019s Registrar Had Not Been Instructed to Accept Blue Proxy Cards Even Though Legally Required to Do So"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53974"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53974\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}